Labcorp
Prix: 266.16Entreprise et modèle économique
Labcorp is a leading healthcare company that provides comprehensive laboratory services and diagnostic solutions. Its core offerings include clinical laboratory testing, drug development services, and genomic testing. The company operates in two major segments: Labcorp Diagnostics and Labcorp Drug Development. Major revenue sources stem from clinical testing services for healthcare providers and pharmaceutical companies, as well as from its extensive portfolio of laboratory tests and clinical trials.
Profil d’investissement
The investment profile of Labcorp is more aligned with value investors, given its stable revenue generation and modest dividend yield. The stock may appeal to those seeking consistent performance rather than aggressive growth, reflecting a balanced approach to risk and potential returns.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 11.37 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 0.6% ≈
- Surprise BPA
- 3.0% conforme
- Volatilité 20 j
- 1.1% stable
- Rendement du dividende
- 1.1% modéré dernière date ex-dividende: 2026-05-29
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-10 00:48 | Conserver | Acheter | Strong performance and solid fundamentals support growth potential. |
| 2026-05-24 02:44 | Vendre | Conserver | Mixed performance; cautious outlook amid market conditions. |
| 2026-05-16 02:42 | Conserver | Vendre | Weak momentum and fundamentals raise significant risk. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-01 12:49 | Robert W. Baird | Objectif relevé | 332 → 334 | 255.97 |
| 2026-04-08 13:14 | Evercore ISI | Objectif relevé | 280 → 300 | 274.72 |
| 2026-02-24 11:40 | Piper Sandler | Objectif relevé | 270 → 300 | 285.3 |
Rien pour le moment